"We made considerable progress across the business during 2022, achieving record sepsis product revenue and sepsis-driven T2Dx Instrument units. We are very excited by the progress on our near-term new product pipeline, the advancement of the U.S. clinical trials for the T2Resistance Panel and the T2Biothreat Panel, and the development of plans for the T2Lyme Panel and expanded T2Bacteria Panel," stated John Sperzel, chairman and CEO of T2 Biosystems. "Heading into 2023, we believe we are well-positioned to accelerate product sales growth, enhance product gross margins, and drive toward profitability."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TTOO:
- T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
- T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.
- T2 Biosystems extends multiyear technology contract with Vizient
- T2 Biosystems highlights peer-reviewed article on COVID-19, sepsis
- T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy
